Haemonetics (NYSE:HAE) Price Target Raised to $78.00 at Needham & Company LLC

Haemonetics (NYSE:HAE) had its target price hoisted by equities research analysts at Needham & Company LLC from $68.00 to $78.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s target price would indicate a potential upside of 10.33% from the stock’s current price.

Several other equities research analysts have also issued reports on HAE. Mizuho dropped their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. BTIG Research increased their price target on shares of Haemonetics from $85.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup reduced their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $78.50.

Haemonetics Stock Up 5.3%

Haemonetics stock traded up $3.59 during midday trading on Friday, hitting $70.70. 765,713 shares of the stock were exchanged, compared to its average volume of 837,053. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of 21.55, a price-to-earnings-growth ratio of 0.91 and a beta of 0.43. Haemonetics has a 52-week low of $47.31 and a 52-week high of $94.99. The business’s 50-day moving average price is $51.25 and its 200-day moving average price is $62.02.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the prior year, the company earned $1.12 EPS. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. GAMMA Investing LLC increased its holdings in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares during the last quarter. Quarry LP increased its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. UMB Bank n.a. increased its position in Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 320 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 567 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.